GlassScriptPhysician profile
Clayton S Syndergaard
NPI 1134106784
$2,954.48
in general payments reported to CMS, 2019-2025
15 companies · $428 in 2025
The $428 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.13 · 2020: $31.20 · 2021: $200 · 2022: $627 · 2023: $708 · 2024: $930 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.11 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.00 | 2019-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $639.18 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.96 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $313.62 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Hologic Sales and Service, LLC | $124.27 | 2020-2021 | |
| Alkermes, INC. | $117.98 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $73.11 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $72.01 | 2023-2025 | Auvelity |
| Indivior INC. | $55.51 | 2021-2024 | Sublocade |
| Janssen Pharmaceuticals, INC | $38.28 | 2024 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $34.23 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $20.94 | 2024 | Fanapt, Hetlioz |
| Coopersurgical, INC. | $15.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.66 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Syndergaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.